Long-term results of dose density therapy in patients with aggressive lymphoma

Autor: Willhelm Oberaigner, Joerg Pont, Hubert Hausmaninger, Werner Linkesch, Richard Greil, Christian Baldinger, Joerg Klocker, O. Krieger, Michael A. Fridrik
Rok vydání: 2004
Předmět:
Zdroj: Annals of Hematology. 84:217-222
ISSN: 1432-0584
0939-5555
DOI: 10.1007/s00277-004-0936-x
Popis: To evaluate the long-term outcome of dose density chemotherapy in the treatment of aggressive lymphoma, we analyzed 142 patients with untreated aggressive lymphoma. Chemotherapy was an eight-drug regimen given in weekly intervals in two prospective trials. The median observation period was 8 years; the longest follow-up was 13 years. Overall survival at 8 years was 0.583. The 8-year survival of patientsor =60 years was significantly better than that of older patients, namely 0.713 vs 0.304 (p=0.000000697). This excellent survival of patients agedor =60 years was identical for high-risk and high-intermediate-risk patients compared with low-risk and low-intermediate-risk patients in the age-adjusted international prognostic index (IPI). The excellent long-term results of the CEOP/IMVP-Dexa regimen (cyclophosphamide, epirubicin, vincristine, and prednisone/ifosfamide with systemic mesna, methotrexate, etoposide, and dexamethasone) for patients agedor =60 years suggest that this regimen might be superior to the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and needs to be tested in comparison to high-dose regimens and novel approaches including antibody treatment.
Databáze: OpenAIRE
Externí odkaz: